Cargando…
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be us...
Autores principales: | Disanto, Giulio, Benkert, Pascal, Lorscheider, Johannes, Mueller, Stefanie, Vehoff, Jochen, Zecca, Chiara, Ramseier, Simon, Achtnichts, Lutz, Findling, Oliver, Nedeltchev, Krassen, Radue, Ernst-Wilhelm, Sprenger, Till, Stippich, Christoph, Derfuss, Tobias, Louvion, Jean-François, Kamm, Christian P., Mattle, Heinrich P., Lotter, Christoph, Du Pasquier, Renaud, Schluep, Myriam, Pot, Caroline, Lalive, Patrice H., Yaldizli, Özgür, Gobbi, Claudio, Kappos, Ludwig, Kuhle, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816556/ https://www.ncbi.nlm.nih.gov/pubmed/27032105 http://dx.doi.org/10.1371/journal.pone.0152347 |
Ejemplares similares
-
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017) -
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020) -
Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018) -
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
por: Achtnichts, Lutz, et al.
Publicado: (2021) -
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
por: Achtnichts, Lutz, et al.
Publicado: (2022)